Encompass Health (EHC) Q2 2025: Occupancy Up 210bps as Bed Expansion Drives Growth Agenda

2025-08-05 | By EarningsIQ Research

Encompass Health’s Q2 saw broad-based discharge growth and a 210 basis point occupancy increase, fueling another upward revision to full-year guidance. Leadership is leaning hard into capacity expansion, with capital allocation priorities centered on new beds and De Novo, new-build hospital, projects, as the company seeks to capture rising demand amid a structurally aging population. Labor stabilization and technology-driven efficiency gains are supporting the margin narrative, but execution risks around benefits costs and the pace of new hospital ramp-up remain key watchpoints for investors.

Summary

• Capacity Expansion Momentum: Aggressive bed additions and new hospitals signal a long runway for growth.
• Labor and Technology Productivity: Centralized hiring and AI initiatives are easing staffing and workflow pressure.
• Guidance Raised Again: Management’s confidence is underpinned by robust demand signals and strong free cash flow.

Performance Analysis

Encompass Health delivered 12% revenue growth in Q2, propelled by a 7.2% increase in total discharges and a 210 basis point year-over-year rise in occupancy to 76.6%. Same store discharges rose 5.7%, with especially strong gains in neurological and stroke cases, up 12% and 6.7% respectively, reflecting the company’s focus on high-acuity, complex cases. Net revenue per discharge benefited from lower bad debt expense, while the payer mix remained stable, with managed care growth driven by the VA Community Care Network, now nearly 18% of managed care business and priced at Medicare rates.

On the cost side, salary and wage inflation was contained to 3.4% per FTE (full-time equivalent), and contract labor costs declined by 15.1% year-over-year, reflecting improved hiring and retention. However, benefits expense per FTE jumped 18%, driven by a higher frequency of large medical claims. Free cash flow increased 31.5% to $186 million for the quarter, and year-to-date free cash flow is up 29.7%. Capital deployment remains heavily weighted toward growth capex for new beds and De Novo hospitals, with buybacks and a dividend increase signaling confidence in cash generation.

• Occupancy Surge: 210bps year-over-year increase in occupancy, with 76.6% portfolio-wide and private room mix at 56%.
• Labor Stabilization: Turnover rates for nurses are near pre-pandemic levels, and centralized talent acquisition is yielding net hiring gains.
• Benefits Cost Spike: 18% increase in benefits expense per FTE, driven by high-dollar medical claims rather than specialty pharma inflation.

Management’s guidance raise is grounded in sustained discharge momentum, capacity expansion, and robust cash flow, but the second half will see higher pre-opening costs and potentially rising bad debt if claims review activity resumes.

Executive Commentary

Strategic Positioning

1. Capacity Expansion as Core Growth Lever

Encompass Health is aggressively expanding capacity through new hospital openings and bed additions, with five more hospitals and up to 50 beds to be added in the second half of 2025. The company’s capital allocation is heavily weighted toward organic growth, with De Novo hospital openings preferred over acquisitions due to superior returns and control over quality. This strategy is enabled by favorable market dynamics: the US population aged 65 and older is growing at a compound annual growth rate of 3%, while IRF, Inpatient Rehabilitation Facility, bed supply remains essentially flat, creating a persistent demand-supply gap.

2. Differentiation Through Clinical Quality and Technology

Clinical outcomes and quality metrics remain a differentiator, with Encompass outperforming industry averages on discharge to community, patient mobility, and satisfaction scores. The company’s proprietary IRF-specific electronic medical record and partnership with Palantir, data analytics platform, are being leveraged to improve documentation, reduce administrative burden, and enhance patient evaluation efficiency. Predictive analytics have driven measurable improvements, including a 30% reduction in fall rates and a 24% improvement in acute care transfer rates since 2020.

3. Labor Market Execution and Retention Initiatives

Centralized talent acquisition and career ladder programs are driving hiring gains and reducing turnover, with net nurse hires up and turnover rates returning to pre-pandemic levels. Efforts to streamline workflows and reduce clinical burden are also supporting retention. While the market for physiatrists, rehabilitation physicians, remains tight, residency partnerships and internal training have stabilized supply, ensuring staffing does not constrain growth.

4. Capital Allocation and Shareholder Returns

With net leverage at two times and strong free cash flow, management is balancing growth capex with increased share repurchases and a higher dividend. M&A is not a near-term focus, as De Novo and bed expansion opportunities offer higher returns and strategic fit. Buybacks are expected to increase as incremental capital becomes available, especially given the favorable cash impact of bonus depreciation from recent tax legislation.

5. Payer Mix and Managed Care Trends

Managed care growth is being driven by the VA Community Care Network, now nearly a fifth of managed care volume and reimbursed at Medicare rates, supporting pricing power and volume stability. Other managed care contracts are seeing standard 2.5% to 3% annual price increases, with no material change in contracting dynamics.

Key Considerations

This quarter’s results highlight Encompass Health’s ability to capitalize on secular demand trends while managing operational complexity and cost headwinds.

Key Considerations:

• Bed Expansion Pipeline: The company’s active development pipeline includes 50 projects, supporting multi-year visibility into growth.
• Labor Productivity Gains: Centralized recruiting and workflow enhancements are offsetting wage inflation and reducing contract labor reliance.
• Benefits Cost Escalation: Rising high-dollar medical claims are a margin risk, with benefits expense now over 10% of SWB, Salaries Wages and Benefits.
• Technology Enablement: AI-driven documentation and predictive analytics are improving efficiency, quality, and staff satisfaction.
• Capital Allocation Discipline: Growth capex remains the priority, but increasing buybacks and dividends reflect confidence in cash generation and balance sheet strength.

Risks

Benefits cost inflation and the risk of higher bad debt expense if claims review activity resumes could pressure margins in the second half. Execution risk around ramping new hospitals and maintaining quality as capacity expands is non-trivial. Regulatory changes, especially around quality metrics or CON, Certificate of Need, laws, could alter the competitive landscape or impact returns on new projects. Tariff volatility and construction cost inflation remain industry-wide watchpoints, though EHC’s current exposure is limited.

Forward Outlook

For Q3 2025, Encompass Health guided to:

• Continued broad-based discharge growth, with new capacity coming online late in the year moderating occupancy rates near-term.
• Pre-opening and ramp-up costs weighted to the second half, with $14 million expected versus $6 million in the first half.

For full-year 2025, management raised guidance:

• Net operating revenue of $5.88 to $5.98 billion
• Adjusted EBITDA of $1.22 to $1.25 billion
• Adjusted EPS of $5.12 to $5.34
• Adjusted free cash flow of $705 to $795 million

Management highlighted robust demand for IRF services, ongoing labor stability, and the impact of bonus depreciation as key drivers supporting the outlook. Investors should watch for:

• Execution on new hospital openings and bed expansions
• Trends in benefits cost and bad debt expense

Takeaways

Encompass Health’s Q2 results reinforce the company’s position as a leading consolidator in inpatient rehabilitation, with growth underpinned by secular demographic trends and operational discipline.

• Capacity-Driven Growth: The combination of new hospital openings, bed additions, and high private room mix is extending EHC’s growth runway and market share gains.
• Labor and Technology Execution: Centralized talent acquisition, workflow optimization, and AI-driven documentation are supporting both quality and margin resilience.
• Margin Watchpoints: Benefits expense escalation and the ramp-up of new capacity will be key variables for margin and free cash flow conversion in the coming quarters.

Conclusion

Encompass Health continues to execute on a capacity-led growth strategy, leveraging quality differentiation and operational discipline to capture expanding demand. While execution risks around cost inflation and new facility ramp are present, the company’s strong balance sheet and capital allocation flexibility provide a solid foundation for sustained shareholder returns.

Industry Read-Through

This quarter’s results highlight a secular tailwind for post-acute care providers, particularly those focused on high-acuity, aging populations. The persistent gap between demand for IRF beds and available supply suggests continued opportunity for scaled operators to expand both organically and via M&A. Labor stabilization and technology adoption are emerging as critical differentiators, with AI and workflow automation increasingly necessary to offset wage and benefits inflation. Regulatory shifts around quality measurement and CON laws could reshape competitive dynamics, especially in high-growth states. Investors should monitor how other post-acute and specialty care providers adapt their strategies in response to these structural forces.

EHC Health Care Post-Acute Capacity Expansion Labor Productivity AI De Novo Benefits Cost